Wikipedia -WSS

Wikipedia

author：focus 2025-09-29 23:04:45 - browse：179

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Type 2 diabetes prevention programs work at large scale: study

WSS

Testing for cancer recurrence creates a new limbo for patients

Diversifying clinical trials isn't enough to close racial gaps: study

Eli Lilly to pay $200M for Beam’s stake in gene

Chimpanzees, like humans and whales, get menopause: Study

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

UnitedHealth sued over use of algorithm in Medicare Advantage plans

entertainment

Wikipedia

focus

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Zepbound, Valneva's vaccine, and more

At least 13 dead in Texas as scorching temps continue

Emergency medicine has repudiated 'excited delirium.' Now what?

The high cost of giving birth even with insurance

Ventyx halts psoriasis drug development after lackluster trial results

Affirmative action in medical school literally saved lives

Medicare’s new pay boost for primary care is angering specialists

Peter Hotez and the public health issue of online harassment

Eli Lilly to pay $200M for Beam’s stake in gene

hotspot

Healthy food access boosts outcomes in two studies

Readout Newsletter: New research from Sanofi, Regeneron, etc.

After decades in use, heart stents finally beat placebo

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Diversifying clinical trials isn't enough to close racial gaps: study

Physician subsidies by hospitals soar in wake of No Surprises Act

focus

entertainment

focus

explore